Objective-It is known that specific plasma ceramides are associated with stress-induced reversible myocardial perfusion defects in patients with established or suspected coronary artery disease undergoing myocardial perfusion scintigraphy (MPS). However, it is currently uncertain whether plasma ceramides are also associated with reduced poststress myocardial perfusion in these patients. Approach and Results-We measured 6 previously identified high-risk plasma ceramide species (ceramide [d18:1/16 in 167 consecutive patients with established or suspected coronary artery disease undergoing stress MPS for clinical indications. Plasma ceramides were measured by a targeted liquid chromatography-tandem mass spectrometry assay both at baseline and after MPS. Multivariable linear regression analysis was undertaken to examine the associations (standardized B coefficients) between plasma ceramides and the percentage of poststress myocardial perfusion after adjustment for multiple cardiovascular risk factors. Seventy-eight patients had stress-induced myocardial ischemia on MPS (mainly located in the anteroapical wall). Of the 6 measured plasma ceramides, higher levels of basal ceramide (d18:1/18:0; B=−0.182; P=0.019), ceramide (d18:1/20:0; B=−0.224; P=0.004), ceramide (d18:1/22:0; B=−0.163; P=0.035), and ceramide (d18:1/24:1; B=−0.20; P=0.010) were associated with lower poststress anteroapical wall perfusion. Notably, these significant associations persisted even after adjustment for conventional cardiovascular risk factors, previous coronary artery disease, electrocardiographic left bundle branch block, left ventricular ejection fraction and type of stress testing. Similar results were observed for poststress plasma ceramides. Conclusions-Higher circulating levels of specific ceramides, both at baseline and after stress, were independently associated with lower poststress anteroapical wall perfusion in patients with suspected or established coronary artery disease referred for clinically indicated MPS. Visual Overview-An online visual overview is available for this article. It is important to understand the factors potentially affecting myocardial perfusion after stress MPS in patients with established or suspected CAD because it is plausible that modifications of these factors may improve myocardial perfusion in situations of stress. The percentage reduction in myocardial perfusion after stress MPS in patients with established or suspected CAD is clinically important because it reflects the coexistence of coronary atherosclerosis. It is currently not known whether basal and poststress levels of these plasma ceramides are associated with a reduction in stress-induced myocardial perfusion on MPS. We consider that this topic may be of clinical importance because it is plausible that increases in plasma ceramide levels may worsen myocardial perfusion in patients at high risk of myocardial ischemia.
C eramides are central molecular species of the sphingolipid pathway, which play a key role as structural lipids and second messengers for intra and intercellular signaling pathways, such as cellular growth, proliferation, differentiation, and apoptosis. 1, 2 During the past years, the importance of specific plasma ceramides (and their metabolites) as possible mediators or biomarkers of complex disease mechanisms, including atherosclerotic processes, has become increasingly evident. [3] [4] [5] Large follow-up studies have recently identified specific plasma ceramides with long and very long chains (that is, ceramide [d18:1/16:0], ceramide [d18:1/18:0], and ceramide [d18:1/24:1]) as predictors of major cardiovascular events both in patients with established coronary artery disease (CAD) and in those with clinical suspicion for acute coronary syndrome, independent of plasma lipid profile and other traditional cardiovascular risk factors. [6] [7] [8] [9] [10] In addition, we have recently reported that there was a significant and independent association between these previously identified high-risk plasma ceramides ( It is important to understand the factors potentially affecting myocardial perfusion after stress MPS in patients with established or suspected CAD because it is plausible that modifications of these factors may improve myocardial perfusion in situations of stress. The percentage reduction in myocardial perfusion after stress MPS in patients with established or suspected CAD is clinically important because it reflects the coexistence of coronary atherosclerosis. It is currently not known whether basal and poststress levels of these plasma ceramides are associated with a reduction in stress-induced myocardial perfusion on MPS. We consider that this topic may be of clinical importance because it is plausible that increases in plasma ceramide levels may worsen myocardial perfusion in patients at high risk of myocardial ischemia.
Therefore, the main aim of this cross-sectional study was to explore whether there was an association between circulating levels of 6 previously identified high-risk plasma ceramides and poststress myocardial perfusion in patients with established or suspected CAD undergoing stress MPS.
Materials and Methods
The authors declare that all supporting data are available within the article (and in the online-only Data Supplement).
Patients
In this analysis, we studied 167 ambulatory patients (128 men and 39 women) with established or suspected CAD, who consecutively underwent stress MPS for various clinical reasons (eg, chest pain, palpitations, dyspnea, suspected ischemic electrocardiographic alterations, echocardiographic abnormalities, or presence of multiple cardiovascular risk factors) at the IRCCS Sacro Cuore Hospital of Negrar (Verona) over a 4-month period. We excluded patients with: (1) a documented history of malignancy, cirrhosis and kidney failure (defined as estimated glomerular filtration rate <15 mL/min per 1.73 meter 2 or chronic dialysis); (2) a documented history of overt hyperthyroidism or hypothyroidism; and (3) presence of active infectious diseases (eg, endocarditis and myocarditis). These 167 patients have been included in a previous study.
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The local Ethics Committee approved the study protocol. All participants gave their written informed consent for participation in this research.
Clinical and Laboratory Data
Body mass index was measured as kilograms divided by the square of height in meters. Patients were considered to have hypertension if their blood pressure was ≥140/90 mm Hg or if they were treated with antihypertensive drugs. Information on smoking history and use of medications was obtained from all patients by interviews during medical examinations.
Venous blood samples were drawn in the morning after an overnight fast. Serum creatinine (measured using a Jaffè rate blanked and compensated assay), lipids, and other biochemical blood parameters were measured using standard laboratory procedures at the central Laboratory of our hospital. Glomerular filtration rate was estimated using the 4-variable MDRD study (Modification of Diet in Renal Disease) equation. 12 Preexisting CAD was defined as a documented history of myocardial infarction, angina or coronary revascularization procedures. The diagnosis of permanent atrial fibrillation or left bundle branch block was made on the basis of medical history (from reviewing hospital and physician charts from all patients) and standard 12-lead ECG. Preexisting history of heart valve diseases was confirmed by reviewing medical records of the hospital and echocardiograms. Previously known diabetes mellitus was defined as self-reported physician-diagnosed diabetes mellitus or use of hypoglycemic medications (insulin or oral agents). Dyslipidemia was defined as a total cholesterol level ≥5.2 mmol/L (≥200 mg/dL) or drug treatment. Chronic kidney disease was defined as the presence of glomerular filtration rate estimated by using the MDRD study equation <60 mL/min per 1.73 meter 2 .
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Plasma Ceramide Measurements
Blood samples for ceramide measurements were obtained in EDTAcontaining tubes both immediately before and after stress MPS. Plasma was collected within 2 hours from withdrawal and stored at −80°C until analysis. An expert laboratory physician, who was blinded to clinical details of participants, performed all measurements of plasma ceramides. Ceramides were purchased from Avanti Polar Lipids, Inc (Alabaster, AL). Plasma concentrations of ceramide (d18:1/16:0), ceramide (d18:1/18:0), ceramide (d18:1/20:0, ceramide (d18:1/22:0), ceramide (d18:1/24:0), ceramide (d18:1/24:1) were measured by liquid-liquid extraction with 2-propanol:ethyl acetate (4:1 v/v) and gradient reverse phase chromatography on an Agilent Poroshell 120 C18 column (4.6×50 mm, 2.7 µm).
11,13 Ceramide (d18:1/17:0) was used as internal standard. The apparatus consisted of an Agilent 1290 UHPLC (ultra-high performance liquid chromatography) system coupled with an Agilent 6495 Triple Quadrupole LC/MS (liquid chromatography/mass spectrometry) system. Mobile phases consisted in LC-MS grade water (A), acetonitrile with 0.1% formic acid (B) and 10 mmol/L ammonium acetate in 2-propanol (C).
[M+H]+→264 MRM (multiple reaction monitoring) transition was selected to quantify each ceramide. Calibration standards (6 points) were daily prepared in surrogate matrix (5% BSA) at concentration range from 1.0 to 0.031 µmol/L per liter for ceramide (d18:1/16:0), ceramide (d18:1/18:0), and ceramide (d18:1/20:0) and from 10 to 0.31 µmol/L per liter for ceramide (d18:1/22:0), ceramide (d18:1/24:0), and ceramide (d18:1/24:1), respectively. Linearity regression coefficient was R 2 >0.99 for all ceramides. Interassay and intraassay coefficients of variations for precision and accuracy for all measured ceramides were <15%. 11 No matrix interference or carryover was observed.
Myocardial Perfusion Scintigraphy
Rest and stress studies were performed by an expert nuclear medicine physician, who was blinded to participants' details, in all patients in a 2-day (2×370 MBq) protocol using technetium-99 m 2-methoxy-isobutyl-isonitrile, according to local standardized clinical routine. 11, 14 In total, 94 (56.3%) patients performed an exercise stress testing using bicycle ergometry and 73 (43.7%) patients performed a pharmacological stress testing with dipyridamole infusion. The pharmacological stress testing was used for patients who were unable to perform a standard exercise stress test. During the bicycle exercise test, technetium-99 m 2-methoxy-isobutyl-isonitrile was injected at peak symptom-limited exercise testing. Bicycle exercise was performed following the Bruce protocol. ECG and blood pressure were recorded at rest and every 2 minutes during exercise and recovery. 2-methoxy-isobutyl-isonitrile was injected at rest and at peak exercise. Images were acquired 60 min after the injection of radiopharmaceutical drug on 2 phases (at baseline and after bicycle ergometry test). The single photon emission computed tomography (SPECT) acquisition protocol usually started with the resting part, followed by SPECT at stress the day after. SPECT was performed using a double-head gamma-camera (Millennium MG, GE) equipped with 2 scintillation detectors, angled 90°, with high resolution and low energy parallel-hole collimators. The protocol included 32 projections, 40-s projections, and 12 frames per cycle used in association with a 15% window centered on the 140-keV photopeak of technetium-99 m 2-methoxy-isobutyl-isonitrile. An expert nuclear medicine physician, who was blinded to the participants' details, including ceramide measurements, classified the amount of inducible myocardial ischemia according to the number of stress-induced myocardial segments affected. 15 Segmental myocardial perfusion was automatically calculated using semiquantitative analysis of gated myocardial perfusion SPECT images and then the percentages of myocardial perfusion at the level of the anteroapical, lateral-posterior and inferior myocardial walls were calculated from polar maps. Also, the ventricular volumes and left ventricular ejection fraction were automatically calculated in all patients, using quantitative analysis of gated myocardial perfusion SPECT images. A similar protocol was used when MPS was performed using a pharmacological stress with intravenous dipyridamole (at a dose of 0.56 mg/kg over 4 minutes) in those patients, who were unable to exercise or who exercised submaximally.
Statistical Analysis
Data are expressed as means±SD or percentages. Pearson correlation coefficients were calculated to examine the univariable linear associations between each plasma ceramide concentration and measures of myocardial perfusion after stress MPS at the level of anteroapical, lateral-posterior and inferior myocardial walls. A multivariable linear regression analysis was used to test the independent association between each plasma ceramide (included as a continuous measure, that is, for each SD increment) and segmental myocardial perfusion on stress MPS after adjusting for multiple cardiovascular risk factors. In particular, we performed 2 forced-entry multivariable linear regression models: the first model was adjusted for age and sex (model 1); and the second model was further adjusted for dyslipidemia, hypertension, smoking, diabetes mellitus, previous CAD, heart rate, electrocardiographic left bundle branch block, left ventricular ejection fraction, and type of stress testing (exercise versus dipyridamole; model 2). Although this is an exploratory, hypothesis-generating study where an adjustment for multiplicity in multivariable linear regression models is not mandatory, we also performed a Benjamini-Hochberg method (6 plasma ceramides x 1 outcome) that is an adaptative linear step-up multiple testing procedure that controls the false discovery rate. 16 This false discovery rate-controlling procedure provides less stringent control of type I errors compared with family-wise error rate controlling procedures (such as the Bonferroni correction), which control the probability of at least 1 type I error. Thus, the Benjamini-Hochberg step-up procedure has greater power, at the cost of increased numbers of type I errors. 16 The covariates included in the aforementioned multivariable linear regression models were selected as potential confounding factors based on their significance in univariate analyses or based on their biological plausibility. A P value <0.05 was considered statistically significant. All statistical analyses were performed using the STATA software, version 14.2. Tables 1 and 2 summarize the main clinical/biochemical characteristics, basal and poststress percentages of myocardial perfusion at the level of anteroapical, lateral-posterior or inferior walls, as well as basal and poststress plasma ceramide concentrations (and their ratios to ceramide [d18:1/24:0]) in 167 ambulatory patients with established or suspected CAD, who consecutively underwent stress MPS for various clinical indications. They were predominantly male (77.2%, n=128) and had a mean age of ≈70 years; 55.8% had a prior history of CAD, 80% had hypertension, ≈95% had dyslipidemia, and 24% had established diabetes mellitus. Among the different types of statins used by the treated patients (61.8% of total), atorvastatin was the most commonly used (73%), followed by simvastatin (22%) and rosuvastatin (5%). A total of 78 (46.7%) patients had stressinduced reversible myocardial perfusion defects on MPS. Of these patients, 28.8% had 1 coronary artery affected, 13.2% had 2 coronary arteries affected, and 4.7% had 3 arteries affected. In particular, these stress-induced reversible myocardial perfusion defects were more commonly observed at the level of the anteroapical wall (75.6% of cases with any myocardial perfusion defects), which is largely supplied by the left anterior descending artery, compared with perfusion defects detected in the lateralposterior (29.5% of cases) or inferior walls (43% of cases) of the myocardium, which are largely supplied by the circumflex coronary artery and the right coronary artery, respectively. Table I in the online-only Data Supplement summarizes the main clinical/biochemical characteristics, basal and poststress percentages of myocardial perfusion at the level of anteroapical, lateral-posterior or inferior walls, as well as basal and poststress plasma ceramides in patients stratified by absence or presence of stress-induced reversible myocardial perfusion defects. As expected, compared with those without any myocardial perfusion defect, patients with inducible myocardial ischemia had lower percentages of myocardial perfusion on anteroapical, latero-posterior and inferior wall, both at rest and after stress MPS, even after adjusting for age and sex. Patients with inducible myocardial ischemia also had higher levels of basal ceramide (d18:1/20:0), ceramide (d18:1/22:0), and ceramide (d18:1/24:1) levels compared with those without inducible myocardial ischemia. Conversely, the circulating levels of plasma ceramide (d18:1/16:0), ceramide (d18:1/18:0), and ceramide (d18:1/24:0), both at baseline and after stress, did not significantly differ between the two groups of patients. Tables II, III , and IV in the online-only Data Supplement show basal and poststress plasma ceramides in patients stratified by sex, electrocardiographic left bundle branch block, or preexisting diabetes mellitus, respectively. Compared with men, women had significantly higher age-adjusted levels of basal and poststress ceramide (d18:1/16:0), ceramide (d18:1/18:0), and ceramide (d18:1/22:0). Conversely, no significant age-and sex-adjusted differences were found in any measured plasma ceramide levels between patients with and without electrocardiographic left bundle branch block, as well as between patients with and those without preexisting diabetes mellitus, except for poststress plasma ceramide (d18:1/20:0) levels. Figure I in the online-only Data Supplement), with poststress anteroapical wall perfusion in the whole sample of patients. Specifically, we found that higher levels of these aforementioned ceramides were significantly associated with lower poststress anteroapical wall perfusion. No significant associations were found between plasma ceramide (d18:1/16:0) and ceramide (d18:1/24:0) levels and poststress anteroapical wall perfusion. Similarly, there were no significant associations between the levels of plasma ceramides and poststress myocardial perfusion at the level of either lateralposterior or inferior myocardial walls (data not shown). Table 3 shows the effect of adjustment for multiple cardiovascular risk factors on the associations between basal plasma ceramides and poststress anteroapical wall perfusion. Higher levels of plasma ceramide (d18:1/18:0), ceramide (d18:1/20:0), ceramide (d18:1/22:0), and ceramide (d18:1/24:1) were significantly associated with lower poststress anteroapical wall perfusion after adjustment for age, sex (model 1) or additional adjustment for established cardiovascular risk factors ; dyslipidemia was defined as a total cholesterol level ≥5.2 mmol/L or lipid-lowering treatment; hypertension was defined as blood pressure ≥140/90 mm Hg or use of any antihypertensive agents. HbA1c levels and information on the use of glucose-lowering agents were available only for patients with known diabetes mellitus (n=40). ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CAD, coronary artery disease; eGFR MDRD , glomerular filtration rate estimated by using the MDRD study (Modification of Diet in Renal Diseases) equation; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; and LDL, low-density lipoprotein. and other potential confounders (model 2). Results remained unchanged even when we further adjusted for systolic blood pressure and treatment for hypertension (instead of hypertension included as a single category) or when patients with known diabetes mellitus (n=40) were excluded from statistical analyses (data not shown).
Results
Almost identical results were observed when the aforementioned multivariable linear regression analyses were repeated including poststress plasma ceramides (Table 4) . Also in such case, poststress levels of plasma ceramide (d18:1/18:0), ceramide (d18:1/20:0), ceramide (d18:1/22:0), and ceramide (d18:1/24:1) were inversely associated with poststress anteroapical wall perfusion after adjusting for several cardiovascular risk factors and potential confounders (models 1 and 2). When we also applied the Benjamini-Hochberg step-up multiple testing procedure in the fully adjusted models 2, we found that basal and poststress levels of plasma ceramide (d18:1/20:0) and plasma ceramide (d18:1/22:0), as well as poststress plasma ceramide (d18:1/18:0) levels maintained conventional statistical significance.
Discussion
The novel finding of this exploratory, hypothesis-generating study is that circulating levels of some previously identified high-risk plasma ceramide species are significantly associated with lower poststress myocardial wall perfusion in patients with history of or clinical suspicion for CAD referred for clinically indicated stress MPS (ie, an accurate imaging technique for the early diagnosis and quantification of CAD). Specifically, higher circulating levels of plasma ceramide (d18:1/18:0), ceramide (d18:1/20:0), ceramide (d18:1/22:0), and ceramide (d18:1/24:1), both at baseline and after stress, were significantly associated with lower poststress anteroapical myocardial wall perfusion, even after adjustment for conventional cardiovascular risk factors, previous CAD, electrocardiographic left bundle branch block, left ventricular ejection fraction, and type of MPS stress. In contrast, plasma levels of ceramide (d18:1/16:0) and ceramide (d18:1/24:0) were not associated with lower anteroapical wall perfusion in this group of high-risk patients.
Overall, these results reinforce and further expand our previous observations showing that higher levels of plasma ceramide (d18:1/16:0), ceramide (d18:1/18:0), ceramide (d18:1/20:0), ceramide (d18:1/22:0), and ceramide (d18:1/24:1) were independently associated with the presence of stress-induced reversible myocardial perfusion defects on MPS in this group of patients. 11 Notably, these plasma ceramides were found to be significantly associated with stress-induced reversible myocardial perfusion defects also in those patients, who were already treated with a statin (most of whom achieving the target LDL (low-density lipoprotein)-cholesterol concentrations), and might, therefore, represent a potential marker of coronary residual risk. 11 At first glance, the lack of any significant association between plasma ceramides and poststress myocardial perfusion at the level of lateral-posterior and inferior walls could appear unexpected. However, the most likely explanation for our finding is that most of the stress-induced reversible myocardial perfusion defects we observed in these patients were mainly located in the anterior-apical wall of the myocardium (≈76% of cases). The perfusion of the anteroapical wall is mostly dependent on the left anterior coronary descending artery, which supplies ≈45% to 55% of the left ventricle and is considered the most critical vessel in terms of myocardial blood supply. Therefore, we consider that the finding of a strong relationship between higher levels of basal and poststress plasma ceramides and lower poststress anterior-apical wall perfusion (ie, the left anterior descending artery area), which was the part of the myocardium more frequently affected by coronary atherosclerosis in our patients with CAD, adds weight to causality and further reinforces the view that specific plasma ceramides may play a role in the pathophysiology of CAD and related clinical outcomes.
In the past few years, plasma ceramides have emerged as potential mediators or biomarkers in many lipid-related diseases, including cardiovascular disease. 1, 2 Recent longitudinal studies reported that distinct ceramide species are associated with increased risk of fatal and nonfatal cardiovascular events in high-risk patient populations, independent of coexisting cardiovascular risk factors. [6] [7] [8] [9] [10] [11] 17 For instance, in a recent longitudinal study of nearly 500 patients undergoing elective coronary angiography, Meeusen et al 6 reported that higher levels of plasma ceramide (d18:1/16:0), ceramide (d18:1/18:0), and ceramide (d18:1/24:1) were associated with an increased risk of major adverse cardiovascular events during a follow-up period of 4 years, even after adjustment for age, sex, body mass index, hypertension, smoking, lipid profile, plasma glucose levels, and family history of CAD. In another longitudinal study of 581 patients, who underwent diagnostic coronary angiography or percutaneous coronary intervention for stable angina pectoris or acute coronary syndrome, Anroedh et al 6 showed that higher levels of plasma ceramide (d18:1/16:0), ceramide (d18:1/20:0), and ceramide (d18:1/24:1) were independently associated with adverse cardiovascular outcomes during a median follow-up of nearly 5 years. 7 Again, Laaksonen et al 9 combining the data of 3 prospective cohort studies of patients with stable CAD or acute coronary syndrome found that higher levels of plasma ceramide (d18:1/16:0), ceramide (d18:1/18:0), and ceramide (d18:1/24:1) were associated with cardiovascular mortality, independently of plasma lipid markers and other traditional cardiovascular risk factors. Finally, recent analysis of individuals in the PREDIMED trial (Prevention with Mediterranean Diet), who were at high cardiovascular risk, indicated that higher ceramide (d18:1/16:0), ceramide (d18:1/22:0), ceramide (d18:1/24:0), and ceramide Sample size, N=167. Data are expressed as standardized β coefficients as tested by linear regression analysis. The percentage of anteroapical wall perfusion after stress MPS was the dependent variable. Each cer was expressed per 1-SD increment. Other covariates included in the multivariate linear regression models (along with specific plasma cer) were as follows: model 1: adjusted for age and sex; model 2: adjusted for age, sex, diabetes mellitus, hypertension (blood pressure ≥140/90 mm Hg or drug treatment), dyslipidemia (total cholesterol level ≥5.2 mmol/L or drug treatment), smoking, heart rate, electrocardiographic left bundle branch block, previous CAD, left ventricular ejection fraction, type of stress on MPS (exercise vs dipyridamole). CAD indicates coronary artery disease; Cer, ceramide; FDR, false discovery rate; and MPS, myocardial perfusion scintigraphy. *Adjusted model 2: these associations remained statistically significant even after adjustment for multiplicity by using the Benjamini-Hochberg step-up procedure (with an FDR of 0.05). Sample size, N=167. Data are expressed as standardized beta coefficients as tested by linear regression analysis. The mean percentage of anteroapical wall perfusion after stress MPS was the dependent variable. Each cer was expressed per 1-SD increment. Other covariates included in the multivariate linear regression models (along with specific plasma cer) were as follows: model 1: adjusted for age and sex; model 2: adjusted for age, sex, diabetes mellitus, hypertension (blood pressure ≥140/90 mm Hg or drug treatment), dyslipidemia (total cholesterol level ≥5.2 mmol/L or drug treatment), smoking, heart rate, electrocardiographic left bundle branch block, previous CAD, left ventricular ejection fraction, type of stress on MPS (exercise vs dipyridamole). CAD indicates coronary artery disease; Cer, ceramide; FDR, false discovery rate; and MPS, myocardial perfusion scintigraphy. *Adjusted model 2: these associations remained statistically significant even after adjustment for multiplicity by using the Benjamini-Hochberg step-up procedure (with an FDR of 0.05).
(d18:1/24:1) levels were associated with a greater risk of incident cardiovascular events and that a Mediterranean dietary intervention might mitigate the potential adverse effect of increased plasma ceramide levels on cardiovascular outcomes. 8 To date, the putative pathophysiological mechanisms by which specific plasma ceramides lead to a reduction of myocardial perfusion after stress MPS are not fully understood. Experimentally, it has been shown that different ceramide species play a key role in many atherosclerotic processes, such as lipoprotein aggregation, uptake of lipoproteins and accumulation of cholesterol within macrophages, regulation of nitric oxide synthesis, production of reactive oxygen species, platelet activation, and expression of various cytokines. 1, 2, [18] [19] [20] [21] [22] Moreover, experimental studies in animals have shown that ceramides are associated with the development of atherosclerosis.
1,2,5 However, further mechanistic studies are needed to better elucidate the role of different plasma ceramides in specific lipid-related diseases and to examine the differential effects of plasma ceramides with various acyl-chain lengths on multiple signaling processes of coronary atherogenesis. Indeed, it is possible to assume that differences in the levels of ceramides with different acyl-chain lengths might display important alterations in the lipidome, thus contributing to differential risk for atherosclerosis.
Our study has some important limitations that should be mentioned. First, the cross-sectional design of the study does not allow for proving a cause-effect relationship. Second, our sample comprised patients with a relatively high cardiovascular risk. Hence, these results might not be necessarily generalizable to other patient populations with low or intermediate cardiovascular risk. Third, after adjusting for multiple comparisons, some of the P values were of borderline statistical significance (in particular, when we applied the Benjamini-Hochberg step-up multiple testing procedure in our fully adjusted regression models, we found that basal and poststress levels of plasma ceramide [d18:1/20:0] and ceramide [d18:1/22:0], as well as poststress plasma ceramide [d18:1/18:0], retained conventional statistical significance). However, we think that the consistency of the results across most of the measured plasma ceramides clearly supports the robustness of our observations. Finally, we cannot exclude the possibility that other unmeasured confounding factors may partly explain the observed associations.
Despite these limitations, our study also has important strengths, such as the consecutive enrollment of patients, the relatively large sample size, the use of stress MPS for detecting myocardial perfusion and ischemia, and the exclusion of patients with a documented history of end-stage renal disease, cirrhosis or cancer. We think the inclusion of patients with these comorbid conditions might have confounded the interpretation of data.
In conclusion, this cross-sectional study shows that specific plasma ceramides, both at baseline and after stress, are significantly associated with lower poststress anteroapical myocardial perfusion in patients with established or suspected CAD undergoing stress MPS for clinical indications. Although further studies are needed to replicate these findings in larger populations, these results add knowledge in the field; and the data emphasize that measurement of specific plasma ceramides may be warranted in patients with established or suspected CAD. It remains to be proven, but we speculate that certain ceramide species could represent new therapeutic targets for the treatment of coronary atherosclerosis.
